Concomitant whole-abdominal radiation and intraperitoneal chemotherapy in advanced ovarian carcinoma: A pilot study

L. A. King, G. O. Downey, R. A. Potish, L. L. Adcock, L. F. Carson, L. B. Twiggs

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Because the use of cisplatin-based chemotherapy for ovarian carcinoma has not significantly improved 5-year survival rates compared with either whole-abdominal radiation (WAR) or single-agent chemotherapy, a pilot study was begun to assess the feasibility of concomitant radiation and chemotherapy. Eleven previously untreated patients with Stages III and IV ovarian carcinoma were treated concomitantly with 2000 cGy of WAR and intraperitoneal (IP) cisplatin followed by additional IP cisplatin after debulking surgery. Toxicity was moderate to severe. Sixty-four percent of patients had Grades 3 to 4 hematologic toxicity, and 36% required hospitalization for sepsis during WAR/IP cisplatin. Hematologic toxicity was less pronounced during IP cisplatin alone. All patients experienced moderate gastrointestinal toxicity. The average percentage of total body weight lost was 13.5%. Fifty-five percent of all patients demonstrated a complete clinical response to therapy, and patients with minimal postoperative residual disease fared better. One patient with persistent disease had acute nonlymphocytic leukemia (ANLL) 24 months after initial diagnosis. No patients with residual disease greater than 20 mm survived, while 50% of patients with less than 20 mm are clinically free of disease. Toxicity appears to be additive with the combination of WAR and IP cisplatin. Therapeutic efficacy was comparable with standard chemotherapy regimens, but no therapeutic or survival advantages were demonstrated with the use of this treatment protocol.

Original languageEnglish
Pages (from-to)2867-2871
Number of pages5
JournalCancer
Volume67
Issue number11
StatePublished - Jan 1 1991
Externally publishedYes

Fingerprint

Radiation
Cisplatin
Carcinoma
Drug Therapy
Residual Neoplasm
Clinical Protocols
Acute Myeloid Leukemia
Sepsis
Hospitalization
Therapeutics
Survival Rate
Body Weight
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

King, L. A., Downey, G. O., Potish, R. A., Adcock, L. L., Carson, L. F., & Twiggs, L. B. (1991). Concomitant whole-abdominal radiation and intraperitoneal chemotherapy in advanced ovarian carcinoma: A pilot study. Cancer, 67(11), 2867-2871.

Concomitant whole-abdominal radiation and intraperitoneal chemotherapy in advanced ovarian carcinoma : A pilot study. / King, L. A.; Downey, G. O.; Potish, R. A.; Adcock, L. L.; Carson, L. F.; Twiggs, L. B.

In: Cancer, Vol. 67, No. 11, 01.01.1991, p. 2867-2871.

Research output: Contribution to journalArticle

King, LA, Downey, GO, Potish, RA, Adcock, LL, Carson, LF & Twiggs, LB 1991, 'Concomitant whole-abdominal radiation and intraperitoneal chemotherapy in advanced ovarian carcinoma: A pilot study', Cancer, vol. 67, no. 11, pp. 2867-2871.
King LA, Downey GO, Potish RA, Adcock LL, Carson LF, Twiggs LB. Concomitant whole-abdominal radiation and intraperitoneal chemotherapy in advanced ovarian carcinoma: A pilot study. Cancer. 1991 Jan 1;67(11):2867-2871.
King, L. A. ; Downey, G. O. ; Potish, R. A. ; Adcock, L. L. ; Carson, L. F. ; Twiggs, L. B. / Concomitant whole-abdominal radiation and intraperitoneal chemotherapy in advanced ovarian carcinoma : A pilot study. In: Cancer. 1991 ; Vol. 67, No. 11. pp. 2867-2871.
@article{14ea36518d3e4b78be7b1d9458a3827c,
title = "Concomitant whole-abdominal radiation and intraperitoneal chemotherapy in advanced ovarian carcinoma: A pilot study",
abstract = "Because the use of cisplatin-based chemotherapy for ovarian carcinoma has not significantly improved 5-year survival rates compared with either whole-abdominal radiation (WAR) or single-agent chemotherapy, a pilot study was begun to assess the feasibility of concomitant radiation and chemotherapy. Eleven previously untreated patients with Stages III and IV ovarian carcinoma were treated concomitantly with 2000 cGy of WAR and intraperitoneal (IP) cisplatin followed by additional IP cisplatin after debulking surgery. Toxicity was moderate to severe. Sixty-four percent of patients had Grades 3 to 4 hematologic toxicity, and 36{\%} required hospitalization for sepsis during WAR/IP cisplatin. Hematologic toxicity was less pronounced during IP cisplatin alone. All patients experienced moderate gastrointestinal toxicity. The average percentage of total body weight lost was 13.5{\%}. Fifty-five percent of all patients demonstrated a complete clinical response to therapy, and patients with minimal postoperative residual disease fared better. One patient with persistent disease had acute nonlymphocytic leukemia (ANLL) 24 months after initial diagnosis. No patients with residual disease greater than 20 mm survived, while 50{\%} of patients with less than 20 mm are clinically free of disease. Toxicity appears to be additive with the combination of WAR and IP cisplatin. Therapeutic efficacy was comparable with standard chemotherapy regimens, but no therapeutic or survival advantages were demonstrated with the use of this treatment protocol.",
author = "King, {L. A.} and Downey, {G. O.} and Potish, {R. A.} and Adcock, {L. L.} and Carson, {L. F.} and Twiggs, {L. B.}",
year = "1991",
month = "1",
day = "1",
language = "English",
volume = "67",
pages = "2867--2871",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "11",

}

TY - JOUR

T1 - Concomitant whole-abdominal radiation and intraperitoneal chemotherapy in advanced ovarian carcinoma

T2 - A pilot study

AU - King, L. A.

AU - Downey, G. O.

AU - Potish, R. A.

AU - Adcock, L. L.

AU - Carson, L. F.

AU - Twiggs, L. B.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - Because the use of cisplatin-based chemotherapy for ovarian carcinoma has not significantly improved 5-year survival rates compared with either whole-abdominal radiation (WAR) or single-agent chemotherapy, a pilot study was begun to assess the feasibility of concomitant radiation and chemotherapy. Eleven previously untreated patients with Stages III and IV ovarian carcinoma were treated concomitantly with 2000 cGy of WAR and intraperitoneal (IP) cisplatin followed by additional IP cisplatin after debulking surgery. Toxicity was moderate to severe. Sixty-four percent of patients had Grades 3 to 4 hematologic toxicity, and 36% required hospitalization for sepsis during WAR/IP cisplatin. Hematologic toxicity was less pronounced during IP cisplatin alone. All patients experienced moderate gastrointestinal toxicity. The average percentage of total body weight lost was 13.5%. Fifty-five percent of all patients demonstrated a complete clinical response to therapy, and patients with minimal postoperative residual disease fared better. One patient with persistent disease had acute nonlymphocytic leukemia (ANLL) 24 months after initial diagnosis. No patients with residual disease greater than 20 mm survived, while 50% of patients with less than 20 mm are clinically free of disease. Toxicity appears to be additive with the combination of WAR and IP cisplatin. Therapeutic efficacy was comparable with standard chemotherapy regimens, but no therapeutic or survival advantages were demonstrated with the use of this treatment protocol.

AB - Because the use of cisplatin-based chemotherapy for ovarian carcinoma has not significantly improved 5-year survival rates compared with either whole-abdominal radiation (WAR) or single-agent chemotherapy, a pilot study was begun to assess the feasibility of concomitant radiation and chemotherapy. Eleven previously untreated patients with Stages III and IV ovarian carcinoma were treated concomitantly with 2000 cGy of WAR and intraperitoneal (IP) cisplatin followed by additional IP cisplatin after debulking surgery. Toxicity was moderate to severe. Sixty-four percent of patients had Grades 3 to 4 hematologic toxicity, and 36% required hospitalization for sepsis during WAR/IP cisplatin. Hematologic toxicity was less pronounced during IP cisplatin alone. All patients experienced moderate gastrointestinal toxicity. The average percentage of total body weight lost was 13.5%. Fifty-five percent of all patients demonstrated a complete clinical response to therapy, and patients with minimal postoperative residual disease fared better. One patient with persistent disease had acute nonlymphocytic leukemia (ANLL) 24 months after initial diagnosis. No patients with residual disease greater than 20 mm survived, while 50% of patients with less than 20 mm are clinically free of disease. Toxicity appears to be additive with the combination of WAR and IP cisplatin. Therapeutic efficacy was comparable with standard chemotherapy regimens, but no therapeutic or survival advantages were demonstrated with the use of this treatment protocol.

UR - http://www.scopus.com/inward/record.url?scp=0025793828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025793828&partnerID=8YFLogxK

M3 - Article

C2 - 2025852

AN - SCOPUS:0025793828

VL - 67

SP - 2867

EP - 2871

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 11

ER -